| A spatially extended stochastic model of the bacterial chemotaxis signalling pathway TS Shimizu, SV Aksenov, D Bray Journal of molecular biology 329 (2), 291-309, 2003 | 194 | 2003 |
| A systems biology dynamical model of mammalian G1 cell cycle progression T Haberichter, B Mädge, RA Christopher, N Yoshioka, A Dhiman, R Miller, ... Molecular systems biology 3 (1), 84, 2007 | 79 | 2007 |
| Dynamics of the inducing signal for the SOS regulatory system in Escherichia coli after ultraviolet irradiation SV Aksenov Mathematical biosciences 157 (1-2), 269-286, 1999 | 39 | 1999 |
| Application of the combined nonlinear-condensation transformation to problems in statistical analysis and theoretical physics SV Aksenov, MA Savageau, UD Jentschura, J Becher, G Soff, PJ Mohr Computer physics communications 150 (1), 1-20, 2003 | 37 | 2003 |
| An integrated approach for inference and mechanistic modeling for advancing drug development SV Aksenov, B Church, A Dhiman, A Georgieva, R Sarangapani, ... FEBS letters 579 (8), 1878-1883, 2005 | 35 | 2005 |
| Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ... Oncoimmunology 9 (1), 1748982, 2020 | 30 | 2020 |
| Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ... European Journal of Pharmaceutical Sciences 109, S39-S46, 2017 | 26 | 2017 |
| Use of a vegf antagonist in treating retinopathy of prematurity G Burian, S Aksenov | 23 | 2016 |
| Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients G Burian, S Aksenov US Patent App. 14/903,749, 2016 | 22 | 2016 |
| Mathematical Model of the SOS Response Regulation of an Excision Repair Deficient Mutant ofEscherichia coliafter Ultraviolet Light Irradiation SV Aksenov, EA Krasavin, AA Litvin Journal of theoretical biology 186 (2), 251-260, 1997 | 19 | 1997 |
| Longitudinal tumor size and neutrophil‐to‐lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced non‐small cell lung cancer treated with … S Gavrilov, K Zhudenkov, G Helmlinger, J Dunyak, K Peskov, S Aksenov CPT: pharmacometrics & systems pharmacology 10 (1), 67-74, 2021 | 18 | 2021 |
| Induction of the SOS response in ultraviolet-irradiated Escherichia coli analyzed by dynamics of LexA, RecA and SulA proteins SV Aksenov Journal of biological physics 25, 263-277, 1999 | 18 | 1999 |
| Population pharmacokinetics of the BTK inhibitor acalabrutinib and its active metabolite in healthy volunteers and patients with B-cell malignancies H Edlund, SK Lee, MA Andrew, JG Slatter, S Aksenov, N Al-Huniti Clinical Pharmacokinetics 58, 659-672, 2019 | 16 | 2019 |
| Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose‐Response Studies. S Aksenov, JC Roberts, G Mugundu, KT Mueller, I Bhattacharya, ... Clinical Pharmacology & Therapeutics 110 (5), 2021 | 14 | 2021 |
| Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients L Ting, S Aksenov, SG Bhansali, R Ramakrishna, P Tang, DE Geller CPT: Pharmacometrics & Systems Pharmacology 3 (2), 1-7, 2014 | 13 | 2014 |
| Some properties of the Lerch family of discrete distributions SV Aksenov, MA Savageau arXiv preprint math/0504485, 2005 | 13 | 2005 |
| Modeling tumor growth and treatment resistance dynamics characterizes different response to gefitinib or chemotherapy in non‐small cell lung cancer M Nagase, S Aksenov, H Yan, J Dunyak, N Al‐Huniti CPT: Pharmacometrics & Systems Pharmacology 9 (3), 143-152, 2020 | 9 | 2020 |
| Individualized treatment strategies for hyperuricemia informed by a semi‐mechanistic exposure‐response model of uric acid dynamics S Aksenov, CC Peck, UG Eriksson, DR Stanski Physiological reports 6 (5), e13614, 2018 | 9 | 2018 |
| A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated … J Leander, M Sunnåker, D Rekić, S Aksenov, UG Eriksson, S Johansson, ... Journal of Pharmacokinetics and Pharmacodynamics 48, 525-541, 2021 | 8 | 2021 |
| Pharmacometric modeling of naloxegol efficacy and safety: impact on dose and label N Al‐Huniti, D Zhou, H Xu, S Aksenov, KH Bui, R Fox, G Helmlinger, ... Clinical Pharmacology & Therapeutics 102 (5), 741-744, 2017 | 8 | 2017 |
